ADPT — Adaptive Biotechnologies Corpor

Is ADPT overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Diagnostics & Research

Overbought As of August 19, 2026

Adaptive Biotechnologies Corpor (ADPT) currently reads Overbought on the MarketMoodz overbought/oversold meter, as of August 19, 2026. The Healthcare name (Diagnostics & Research) last closed at $25.49. The rating moved from Neutral to Overbought on August 19, 2026.

See all overbought Healthcare stocks →

AI analysis

Adaptive Biotechnologies operates a differentiated immune‑sequencing platform with commercial and collaboration revenue streams and a large clinical data asset base. Diagnostic and screening demand tailwinds are supportive, but near‑term performance depends on reimbursement outcomes, execution on commercial expansion and partnership milestones. The broader market tone is neutral, so meaningful near‑term upside will likely require clear operational beats or positive regulatory/partner news; conversely, dilution or reimbursement setbacks could pressure the share price. Social sentiment and EDGAR filings were not available in the provided window, so assessment relies on sector context and typical biotech operating risks.

Key factors

  • Proprietary immune‑sequencing platform and growing clinical / research data assets that support diagnostic and therapeutic discovery use cases
  • Diversified revenue mix from testing, services and collaborations which can provide recurring and milestone-linked cash inflows
  • Sector tailwinds for diagnostics and screening (AI-enabled navigation and increased procedure volumes) may increase demand for advanced diagnostic assays
  • Strategic partnerships and pharma collaborations that can validate technology and provide potential non-dilutive funding or milestone upside
  • Current market backdrop is neutral with selective interest in growth names, reducing probability of a large near-term re-rating absent clear catalysts
  • Valuation and capital runway constraints have historically pressured similar biotech names, making near-term upside contingent on execution and reimbursement progress

Risks

  • Reimbursement and payer pressure that could reduce test volumes or pricing, amplified by broader payer margin rationalization
  • Execution risk on commercial rollouts, new product adoption, and partnership milestones
  • Continued cash burn and potential need for additional capital, which could dilute shareholders or constrain operations
  • Competitive threats from other sequencing, diagnostics and immunology companies with overlapping offerings
  • Regulatory and clinical validation risk for new assays or claims that materially impact commercialization timelines
  • Macro and sentiment-driven volatility in growth/biotech stocks that can depress multiples despite fundamental progress

Latest MarketMoodz coverage

See today's live rating, score and targets

Members see the live hourly rating for ADPT — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.